17607 Gold Plaza, Omaha, NE
402-991-8468
Patient Portal
Menu

News

Apalutamide Granted FDA’s Priority Review for Nonmetastatic CRPC

December 26, 2017

Based on data from the phase III SPARTAN trial (ARN-509-003), apalutamide (ARN-509) has been granted a priority review by the FDA for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.

View Article

J&J announces positive data from the SPARTAN trial of apalutamide (ARN-509)

October 13, 2017

Janssen Biotech has submitted a New Drug Application to the US Food & Drug Administration for the approval of apalutamide (formerly ARN-509) in the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC).

View Article

First-Line Immunotherapy for Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

October 13, 2017

first-line pembrolizumab (Keytruda) produced durable responses in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer in the phase II KEYNOTE-052 trial.

View Article

CMS’ 340B Reform Proposal Is a Good – Long Overdue – First Step

October 11, 2017

The 340B Drug Discount Program is an innocent-sounding program with the best of intentions. But behind it lies a classic tale of government run amok. After 25 years, this critically important safety net for patients in need has been overrun by some “corporate” hospitals that masquerade as nonprofits. While these bad actors make a killing off of 340B, the very patients it was intended to benefit suffer — and all of us taxpayers foot the bill.

View Article

Nivolumab Plus Ipilimumab vs Sunitinib Alone as First- Line Therapy for Metastatic Renal Cell Carcinoma

October 11, 2017

A CHANGE IN PARADIGM may be on the horizon for the treatment of metastatic renal cell carcinoma. According to the results of CheckMate 214, the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) outperformed the standard of care—sunitinib (Sutent)—for first-line treatment, with improved overall response rates, progression-free survival, as well as the gold standard—overall survival in intermediate- and poor-risk patients.

View Article